Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer
Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer
Active, not recruiting · NCT03468218 · Registry updated 2026-01-23Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, carcinoma, epithelial neoplasm, head and neck squamous cell carcinoma, neoplasm, paranasal sinus squamous cell carcinoma, squamous cell carcinoma | Active, not recruiting | Phase 2 | 2026-01-23 | NCT03468218 |
4 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Emory University | 393 |
| Exelixis | 77 |
| National Cancer Institute (NCI) | 3015 |
| National Institutes of Health (NIH) | 667 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Emory University Hospital Midtown | Atlanta | United States | 246 |
| Moffitt Cancer Center | Tampa | United States | 523 |